| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | EMT; EMTH; OCT3 |
| WB Predicted band size | 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC22A3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC22A3抗体的3篇参考文献的简要总结(注：以下内容为示例性虚构，实际文献需通过学术数据库检索)：
---
1. **文献名称**：*"SLC22A3 Expression in Breast Cancer: Prognostic Implications and Antibody Validation"*
**作者**：Smith J, et al. (2020)
**摘要**：通过免疫组化(IHC)和Western blot验证了SLC22A3抗体在乳腺癌组织中的特异性，发现SLC22A3低表达与患者预后不良相关，提示其可能作为肿瘤抑制因子发挥作用。
2. **文献名称**：*"Functional Characterization of SLC22A3 in Hepatic Drug Transport Using Knockout Models"*
**作者**：Johnson R, et al. (2018)
**摘要**：利用特异性抗体研究SLC22A3蛋白在小鼠肝脏中的定位及功能，证实其参与了他汀类药物的跨膜转运，抗体特异性通过siRNA敲低实验验证。
3. **文献名称**：*"SLC22A3 Genetic Variants Alter Protein Stability Revealed by Immunoblot Analysis"*
**作者**：Lee H, et al. (2019)
**摘要**：通过Western blot结合抗体验证了SLC22A3基因多态性(如rs2504954)对蛋白稳定性的影响，发现特定突变导致蛋白表达水平下降，可能与心血管疾病风险相关。
---
如需真实文献，建议在PubMed或Google Scholar中检索关键词“SLC22A3 antibody validation”或“SLC22A3 immunohistochemistry”。
The SLC22A3 antibody targets the solute carrier family 22 member 3 (SLC22A3), a polyspecific organic cation transporter encoded by the SLC22A3 gene located on human chromosome 6q25.3. SLC22A3. also known as OCT3. facilitates the transport of organic cations, including endogenous compounds (e.g., dopamine, epinephrine) and exogenous drugs (e.g., metformin, cisplatin), across cell membranes. It is expressed in various tissues, such as the liver, kidney, placenta, and blood-brain barrier, playing critical roles in drug disposition, toxin clearance, and neurotransmitter regulation.
Research on SLC22A3 has linked it to diseases like cancer, diabetes, and cardiovascular disorders, where its dysregulation may influence drug response or disease progression. For example, SLC22A3 polymorphisms are associated with altered pharmacokinetics of anticancer drugs, while its overexpression in tumors may affect chemoresistance. The SLC22A3 antibody is widely used in biomedical research to detect protein expression levels, cellular localization, and functional studies via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validating antibody specificity is crucial due to potential cross-reactivity with homologous transporters (e.g., OCT1/OCT2). Understanding SLC22A3's role through antibody-based assays aids in elucidating its physiological and pathological mechanisms, offering insights into therapeutic targeting and personalized medicine strategies.
×
